Literature DB >> 23494931

The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial.

M Spitzer1, S Basaria, T G Travison, M N Davda, L DeRogatis, S Bhasin.   

Abstract

The relationship between testosterone, well-being and mood is poorly understood. We investigated the effect of testosterone supplementation on mood, well-being, and self-reported health in men with erectile dysfunction (ED) and low serum testosterone levels. This was a randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov registration number NCT00512707), in which 140 men, 40-70 years, with ED and low serum testosterone levels were first optimized on sildenafil alone for 3-7 weeks and then randomized to receive either sildenafil plus testosterone gel (n = 70) or sildenafil plus placebo (n = 70) gel for 14 weeks. Using multiple imputations and generalized linear regression, we compared psychological changes in well-being, evaluated by the Psychological General Well-Being Index, and mood, evaluated by Derogatis Affects Balance Scale. Mood and well-being scores were similar between the two groups at baseline and did not substantially change during the administration of sildenafil or after randomization to testosterone. Our findings show that the addition of testosterone to sildenafil in men with ED and low serum testosterone levels was not associated with improvement in either well-being or mood.
© 2013 American Society of Andrology and European Academy of Andrology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494931      PMCID: PMC3630276          DOI: 10.1111/j.2047-2927.2013.00075.x

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  22 in total

Review 1.  The International Index of Erectile Function (IIEF): a state-of-the-science review.

Authors:  R C Rosen; J C Cappelleri; N Gendrano
Journal:  Int J Impot Res       Date:  2002-08       Impact factor: 2.896

2.  Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Authors:  Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

3.  Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial.

Authors:  S N Seidman; E Spatz; C Rizzo; S P Roose
Journal:  J Clin Psychiatry       Date:  2001-06       Impact factor: 4.384

4.  Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial.

Authors:  Matthew Spitzer; Shehzad Basaria; Thomas G Travison; Maithili N Davda; Amanda Paley; Beth Cohen; Norman A Mazer; Philip E Knapp; Samson Hanka; Kishore M Lakshman; Jagadish Ulloor; Anqi Zhang; Katie Orwoll; Richard Eder; Lauren Collins; Nurahmed Mohammed; Raymond C Rosen; Leonard DeRogatis; Shalender Bhasin
Journal:  Ann Intern Med       Date:  2012-11-20       Impact factor: 25.391

5.  Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).

Authors:  Jacques Buvat; Francesco Montorsi; Mario Maggi; Hartmut Porst; Antti Kaipia; Marie Helène Colson; Beatrice Cuzin; Ignacio Moncada; Antonio Martin-Morales; Aksam Yassin; Eric Meuleman; Ian Eardley; John Daniel Dean; Ridwan Shabsigh
Journal:  J Sex Med       Date:  2011-01       Impact factor: 3.802

6.  Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts.

Authors:  Shalender Bhasin; Michael Pencina; Guneet Kaur Jasuja; Thomas G Travison; Andrea Coviello; Eric Orwoll; Patty Y Wang; Carrie Nielson; Frederick Wu; Abdelouahid Tajar; Fernand Labrie; Hubert Vesper; Anqi Zhang; Jagadish Ulloor; Ravinder Singh; Ralph D'Agostino; Ramachandran S Vasan
Journal:  J Clin Endocrinol Metab       Date:  2011-06-22       Impact factor: 5.958

7.  Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging.

Authors:  G Cavallini; S Caracciolo; G Vitali; F Modenini; G Biagiotti
Journal:  Urology       Date:  2004-04       Impact factor: 2.649

8.  Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.

Authors:  R Shabsigh; J M Kaufman; C Steidle; H Padma-Nathan
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

9.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms.

Authors:  R C Rosen; S N Seidman; M A Menza; R Shabsigh; S P Roose; L J Tseng; J Orazem; R L Siegel
Journal:  Int J Impot Res       Date:  2004-08       Impact factor: 2.896

View more
  2 in total

1.  Total osteocalcin in serum predicts testosterone level in male type 2 diabetes mellitus.

Authors:  Ran Cui; Bin Su; Chunjun Sheng; Xiaoyun Cheng; Peng Yang; Le Bu; Hong Li; Jiying Wang; Hui Sheng; Shen Qu
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Circulating Sex Steroids and Vascular Calcification in Community-Dwelling Men: The Framingham Heart Study.

Authors:  Thomas G Travison; Christopher J O'Donnell; Shalender Bhasin; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; Ralph B D'Agostino; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2016-03-01       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.